Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01600846 · ClinicalTrials.gov registry record
Pharmacogenetic Testing in Primary Care
A clinical trial of Pharmacogenetic Testing, sponsored by Duke University.
- Completed
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT01600846: Completed study of Pharmacogenetic Testing, sponsored by Duke University.
NCT01600846 is a study of Pharmacogenetic Testing that has completed, run by Duke University. The registered enrollment target is 400 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01600846, a study of Pharmacogenetic Testing, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to further integrate pharmacogenetic (PGx) testing into clinical practice by educating physicians about pharmacogenetics and offering testing to their patients. Pharmacogenetic testing may help physicians choose the best drug and dosage for their patients which can reduce side effects, increase effectiveness, and improve patient adherence. Two clinics will be involved. One clinic will have a pharmacist on-site as a resource to physicians and to advise what patients may benefit from PGx testing; the other clinic will have a pharmacist on call. Patient and physician perspectives about PGx testing and their utilization will be examined via surveys. The investigators hypothesize that with education about PGx testing, more physicians will utilize testing.
Conditions Studied
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-07 |
What the finished NCT01600846 record still lists
NCT01600846 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Pharmacogenetic Testing appearing as the primary indexed condition, and to 0 interventions.
NCT01600846 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01600846 about?
NCT01600846 is a clinical study titled "Pharmacogenetic Testing in Primary Care". The purpose of this study is to further integrate pharmacogenetic (PGx) testing into clinical practice by educating physicians about pharmacogenetics and offering testing to their patients. Pharmacogenetic testing may help physicians choose the best drug and dosage for their patients which can reduc...
What is the current status of trial NCT01600846?
This trial is currently completed. The enrollment target is 400 participants. The study started on 2012-12. Estimated completion is 2013-07.
What conditions does trial NCT01600846 study?
This clinical trial studies the following conditions: Pharmacogenetic Testing.
Who is sponsoring clinical trial NCT01600846?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01600846 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacogenetic Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia